Skip to main content
TipRanks
Go Ultimate75% OFF

Guard Therapeutics International AB (5LH0) AI Stock Analysis

1 Followers
DE:5LH0

Guard Therapeutics International AB

(Frankfurt:5LH0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetThe absence of debt limits interest obligations and refinancing exposure, giving Guard Therapeutics greater financial flexibility than a leveraged development-stage peer. This clean capital structure can help preserve strategic options while the company advances its clinical programs.
Negative Factors
No commercial revenueZero reported revenue means the company has not yet demonstrated commercial traction or an internally generated funding base. Its financial outlook therefore remains dependent on successful clinical progress, regulatory advancement, and eventual product commercialization.

Guard Therapeutics International AB (5LH0) vs. iShares MSCI Germany ETF (EWG)

-250%0%250%500%750%1000%1250%DE:5LH0+560.00%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 3.84M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.4
Beta (1Y)
-57.48
Revenue Growth
―
EPS Growth
80.07%
Country
Germany
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Guard Therapeutics International AB Business Overview & Revenue Model

Company Description

Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard...

Guard Therapeutics International AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:5LH0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ELICSE:ELIC45NeutralSEK 164.51M-6.88-56.09%――14.10%
SE:SPAGOSE:SPAGO42NeutralSEK 35.13M-1.05-87.37%―-97.52%31.31%
SE:MODTXSE:MODTX39UnderperformSEK 25.61M-0.83-177.45%――0.22%
SE:ONCOZSE:ONCOZ39UnderperformSEK 82.80M-1.28-970.69%―115.26%-230.43%
SE:ACESE:ACE38UnderperformSEK 79.85M-1.38-62.23%――50.59%

* Healthcare Sector Average

Performance Comparison

0%200%400%DE:5LH0SE:ONCOZSE:ELICSE:ACESE:MODTXSE:SPAGODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:5LH0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:5LH0Guard Therapeutics International AB0.070.04200.00%
SE:ONCOZOncoZenge AB3.00-1.65-35.44%
SE:ELICElicera Therapeutics AB2.44-2.63-51.84%
SE:ACEAscelia Pharma AB0.59-2.21-78.93%
SE:MODTXModus Therapeutics Holding AB0.14-0.23-62.43%
SE:SPAGOSpago Nanomedical AB0.04-0.05-54.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.